CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer

Gastroenterology

Volumn 147, Issue 3, 2014, Pages 637-645

  Shiovitz, Stacey ^a,b   Bertagnolli, Monica M ^c   Renfro, Lindsay A ^d   Nam, Eunmi ^e   Foster, Nathan R ^d   Dzieciatkowski, Slavomir ^b   Luo, Yanxin ^b,f   Lao, Victoria Valinluck ^b,g   Monnat, Raymond J ^g   Emond, Mary J ^g   Maizels, Nancy ^g   Niedzwiecki, Donna ^h   Goldberg, Richard M ⁱ   Saltz, Leonard B ^j   Venook, Alan ^k   Warren, Robert S ^k   Grady, William M ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MAYO CLINIC   (United States)

^e Ewha Womans University School of Medicine   (South Korea)

^f SUN YAT SEN UNIVERSITY   (China)

^g UNIVERSITY OF WASHINGTON   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ OHIO STATE UNIVERSITY   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

CALGB (Alliance) 89803; Chemotherapy; CRC; Epigenetic Factors

Indexed keywords

B RAF KINASE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; NEUROGENIN 1; SOMATOMEDIN B; SUPPRESSOR OF CYTOKINE SIGNALING 1; TRANSCRIPTION FACTOR RUNX3;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; COHORT ANALYSIS; COLON ADENOCARCINOMA; CONTROLLED STUDY; CPG ISLAND; CPG ISLAND METHYLATOR PHENOTYPE; DISEASE FREE SURVIVAL; DNA ISOLATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME;

CALGB (ALLIANCE) 89803; CHEMOTHERAPY; CRC; EPIGENETIC FACTORS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COLECTOMY; COLONIC NEOPLASMS; CPG ISLANDS; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA MISMATCH REPAIR; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84906935203     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2014.05.009     Document Type: Article

References (34)

1. A. Walther, E. Johnstone, and C. Swanton et al. Genetic prognostic and predictive markers in colorectal cancer Nat Rev Cancer 9 2009 489 499
2. S. Popat, R. Hubner, and R.S. Houlston Systematic review of microsatellite instability and colorectal cancer prognosis J Clin Oncol 23 2005 609 618 (Pubitemid 46224239)
3. S. Ogino, K. Shima, and J.A. Meyerhardt et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803 Clin Cancer Res 18 2012 890 900
4. T. Andre, C. Boni, and L. Mounedji-Boudiaf et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer N Engl J Med 350 2004 2343 2351 (Pubitemid 38702845)
5. L.B. Saltz, J.V. Cox, and C. Blanke et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group N Engl J Med 343 2000 905 914
6. L.B. Saltz, D. Niedzwiecki, and D. Hollis et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803 J Clin Oncol 25 2007 3456 3461 (Pubitemid 47310883)
7. M.M. Bertagnolli, D. Niedzwiecki, and C.C. Compton et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803 J Clin Oncol 27 2009 1814 1821
8. M.M. Bertagnolli, M. Redston, and C.C. Compton et al. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer - a study of CALGB 9581 and 89803 J Clin Oncol 29 2011 3153 3162
9. A.D. Roth, S. Tejpar, and M. Delorenzi et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial J Clin Oncol 28 2010 466 474
10. A. Mohindra, L.E. Hays, and E.N. Phillips et al. Defects in homologous recombination repair in mismatch-repair-deficient tumour cell lines Hum Mol Genet 11 2002 2189 2200 (Pubitemid 34994007)
11. S. Sharma, K.M. Doherty, and R.M. Brosh Jr. Mechanisms of RecQ helicases in pathways of DNA metabolism and maintenance of genomic stability Biochem J 398 2006 319 337 (Pubitemid 44453376)
12. W.M. Grady, and J.M. Carethers Genomic and epigenetic instability in colorectal cancer pathogenesis Gastroenterology 135 2008 1079 1099
13. S. Ogino, T. Kawasaki, and G.J. Kirkner et al. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample J Mol Diagn 9 2007 305 314 (Pubitemid 47305066)
14. M. Toyota, N. Ahuja, and M. Ohe-Toyota et al. CpG island methylator phenotype in colorectal cancer Proc Natl Acad Sci U S A 96 1999 8681 8686 (Pubitemid 29354851)
15. N. Hawkins, M. Norrie, and K. Cheong et al. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability Gastroenterology 122 2002 1376 1387 (Pubitemid 34465180)
16. D.J. Weisenberger, K.D. Siegmund, and M. Campan et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer Nat Genet 38 2006 787 793 (Pubitemid 43980599)
17. M. van Rijnsoever, F. Grieu, and H. Elsaleh et al. Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands Gut 51 2002 797 802 (Pubitemid 35408598)
18. B.H. Min, J.M. Bae, and E.J. Lee et al. The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy BMC Cancer 11 2011 344
19. C.C. Pritchard, and W.M. Grady Colorectal cancer molecular biology moves into clinical practice Gut 60 2011 116 129
20. M. Van Rijnsoever, H. Elsaleh, and D. Joseph et al. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer Clin Cancer Res 9 2003 2898 2903 (Pubitemid 36993247)
21. R. Jover, T.P. Nguyen, and L. Perez-Carbonell et al. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer Gastroenterology 140 2011 1174 1181
22. L. Shen, P.J. Catalano, and A.B. Benson 3rd et al. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy Clin Cancer Res 13 2007 6093 6098 (Pubitemid 350075067)
23. R.L. Ward, K. Cheong, and S.L. Ku et al. Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability J Clin Oncol 21 2003 3729 3736 (Pubitemid 46606226)
24. S. Ogino, J.A. Meyerhardt, and N. Irahara et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803 Clin Cancer Res 15 2009 7322 7329
25. R.S. Warren, C.E. Atreya, and D. Niedzwiecki et al. Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803 Clin Cancer Res 19 2013 5777 5787
26. S. Ogino, T. Kawasaki, and M. Brahmandam et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis J Mol Diagn 8 2006 209 217 (Pubitemid 43811244)
27. B. Iacopetta, K. Kawakami, and T. Watanabe Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup? Int J Clin Oncol 13 2008 498 503
28. G.L. Anderson, M. Limacher, and A.R. Assaf et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial JAMA 291 2004 1701 1712 (Pubitemid 38489892)
29. H. Zouridis, N. Deng, and T. Ivanova et al. Methylation subtypes and large-scale epigenetic alterations in gastric cancer Sci Transl Med 4 2012 156ra140
30. I. Garrido-Laguna, K. McGregor, and M. Wade et al. Testing targeted demethylation to overcome resistance to epidermal growth factor receptor (EGFR) blocking agents in wild-type (wt) KRAS metastatic colorectal cancer patients (mCRC) J Clin Oncol 30 2012 suppl; abstr 3057
31. S. Ogino, J.A. Meyerhardt, and T. Kawasaki et al. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma Virchows Arch 450 2007 529 537 (Pubitemid 46676250)
32. K. Kawakami, A. Matsunoki, and M. Kaneko et al. Long interspersed nuclear element-1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype-negative colorectal cancer Cancer Sci 102 2011 166 174
33. V.A. Bohr Rising from the RecQ-age: the role of human RecQ helicases in genome maintenance Trends Biochem Sci 33 2008 609 620
34. R.D. Kennedy, and A.D. D'Andrea DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes J Clin Oncol 24 2006 3799-808